World Health Organization & AstraZeneca

World Health Organization: The World Health Organization>>> has declared the Ebola outbreak a public health emergency of international concern and is coordinating the international response, providing experts, supplies, and guidance, though it faces criticism for delayed detection and underestimation of the outbreak's scale.

AstraZeneca: AstraZeneca was involved in the development of the COVID-19 vaccine platform that is now being considered for a Bundibugyo ebolavirus vaccine, showcasing its role in vaccine innovation.

World Health Organization: Leading the international response, declaring a PHEIC, recommending vaccine trials, and adding a diagnostic test to its Emergency Use Listing. Its credibility is tied to the success of the response.

AstraZeneca: Its COVID-19 vaccine technology is used in the Oxford candidate, but AstraZeneca itself is not directly involved in the Ebola response.

World Health Organization: Coordinating vaccine allocation and clinical trials, but facing uncertainty about vaccine efficacy against the current strain. Its guidance is critical for the response.

AstraZeneca: Technology from its COVID-19 vaccine is used in the Oxford Ebola vaccine, indirectly involved.

World Health Organization: The World Health Organization (WHO) has declared the outbreak a public health emergency and is involved in monitoring cases and coordinating the global health response.

AstraZeneca: AstraZeneca is mentioned in the context of the University of Oxford's vaccine technology, which is similar to their COVID-19 vaccine.

World Health Organization: WHO's strain selection process may benefit from faster mRNA vaccine production.

AstraZeneca: AstraZeneca's flu vaccine portfolio could be affected by the entry of mFLUSIVA.

World Health Organization: WHO continues to maintain that benefits of COVID-19 vaccination outweigh risks for recommended groups, but is not directly involved in Germany's policy change.

AstraZeneca: AstraZeneca's vaccine was previously suspended for under 60s in Germany in 2021 due to blood clot concerns; not directly affected by current policy.